MoneyTree™ Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA)

May 2014
  • Print-friendly version
MoneyTree™ Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA)

At a glance

Investments increased year over year for biotech as well as medical devices. The average deal size for early stage medical device investments was the highest since 1995. However, life sciences investments underperformed total venture capital investments and are now at the lowest proportion of total investments since 2001.

Regional funding trends: The San Francisco Bay area, Boston, New York Metro, San Diego Metro, and Orange County received the most life sciences venture capital dollars during the first quarter of 2014. The leader, San Francisco Bay area, received $479 million, with $277 million going to biotechnology and the remaining $201 million going to medical devices. The San Francisco Bay area closed 47 deals during the first quarter of 2014, with an average size of $10.2 million.

Further reading

MoneyTree™ venture capital funding: Falling behind
MoneyTree™ venture capital funding: Biotech boost
MoneyTree™ venture capital funding: Capital crunch
MoneyTree™: Biotech deals rising